Yu, Bin

Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 125

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B

Cancer-related Molecular PathwaysProtein Degradation and Inhibitors

Cited by 106

Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: A meta-analysis of 11 cohort studies

Cai, H., Xu, Z., Xu, T., Yu, B., & Zou, Q. (2015) · Diabetes/Metabolism Research and Reviews

Metabolism, Diabetes, and CancerProstate Cancer Treatment and Research

Cited by 80

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Tang, K., Zhao, M., Wu, Y.-H., Wu, Q., Wang, S., Dong, Y., Yu, B., Song, Y., & Liu, H.-M. (2022) · European Journal of Medicinal Chemistry

Protein Tyrosine PhosphatasesComputational Drug Discovery Methods

Cited by 20